CORAL study chair Lance Dworkin, MD, discusses the controversial finding with Renal & Urology News.
Latest Anemia News
The medication may represent a new treatment option for dialysis patients, researchers concluded.
Soluble ferric pyrophosphate is given to hemodialysis patients via dialysate.
Levels below 10 g/dL found to increase risk of a composite endpoint of all-cause mortality, cerebrovascular events, and myocardial infarction.
Over 52 weeks, the drug maintained hemoglobin levels while decreasing IV iron use in dialysis patients with anemia.
Benefit seen among anemia and hemodialysis patients with hemoglobin levels below 10 g/dL.
Renal events are significantly less likely if erythropoiesis-stimulating agents are started at hemoglobin levels below 11 g/dL.
New finding on vitamin B6 is the opposite of what investigators hypothesized on patients with anemia.
IV iron in anemia hemodialysis patients hospitalized for bacterial infections found not to worsen outcomes.
Use of erythropoiesis-stimulating agents in anemia patients decreased, while use of iron increased.
Hemoglobin level below 8 mg/dL associated with 82% increased odds of prolonged bleeding time with anemia.
Highest quintile of hemoglobin associated with 6-fold increased odds of complete or partial recovery of anemia in acute kidney injury (AKI).
Researchers believe nocturnal home hemodialysis (NHHD) performed every other night may be superior to NHHD performed 6 or 7 times a week.
Hemodialysis patients with a higher percentage of fat tissue respond better to erythropoiesis-stimulating agents.
Low hemoglobin levels increase the risk of death, sepsis, and cerebrovascular accidents following cardiac surgery.
Doses higher than 70 μg per week were associated with a 77% greater risk of cancer compared with non-use of the agents.